Enlivex Therapeutics Ltd. (ENLV)
- Previous Close
1.5000 - Open
1.5500 - Bid 1.4300 x 100
- Ask 1.5400 x 100
- Day's Range
1.4200 - 1.5500 - 52 Week Range
1.1500 - 4.5900 - Volume
32,844 - Avg. Volume
182,904 - Market Cap (intraday)
27.465M - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5600 - Earnings Date Jun 24, 2024 - Jun 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
www.enlivex.comRecent News: ENLV
Performance Overview: ENLV
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENLV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENLV
Valuation Measures
Market Cap
28.22M
Enterprise Value
1.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.94
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.09%
Return on Equity (ttm)
-66.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.07M
Diluted EPS (ttm)
-1.5600
Balance Sheet and Cash Flow
Total Cash (mrq)
27.32M
Total Debt/Equity (mrq)
3.43%
Levered Free Cash Flow (ttm)
-17.77M
Research Analysis: ENLV
Company Insights: ENLV
ENLV does not have Company Insights